015 Indirect comparison of ixekizumab versus guselkumab up to week 12

Biologics are effective for the treatment of psoriasis, but head-to-head studies comparing the efficacy of the recently approved biologics are lacking for certain comparators of interest. Here, we indirectly compared psoriasis clinical trial efcacy data between ixekizumab (IXE), a selective interleukin (IL)-17A antagonist,and guselkumab (GUS), a recently approved IL-23 p19 inhibitor. We used the adjusted indirect comparison (AIC) Bucher method (BU) and two modied Signorovitch methods (SG) matching for overall or adjusting for baseline characteristics and effect modifiers to compare IXE 80 mg every 2 weeks (IXEQ2W) to GUS 100 mg (week 0, 4, 12) via the common comparator (bridge), placebo, with respect to Psoriasis Area Severity Index (PASI) response rates over the rst 12 weeks.

Source: Journal of Investigative Dermatology - April 19, 2018 Category: Dermatology Authors: A. Gottlieb, Y. Ramot, S. Smith, D. Saure, A. Schacht, M. Dossenbach, S. Wilhelm, D. Thaci Tags: Adaptive and Auto-Immunity Source Type: research